NCT05470777 CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL Status RECRUITING Phase PHASE2
NCT05460533 A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL) Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT05333302 Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma Status RECRUITING Phase PHASE1
NCT05262673 NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL Status RECRUITING Phase PHASE1
NCT05210907 Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic Leukemia Status RECRUITING Phase PHASE1
NCT05082519 Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL Status RECRUITING Phase PHASE2
NCT05020678 NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT04844086 RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies Status TERMINATED Phase PHASE1
NCT04595162 A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL Status NOT_YET_RECRUITING Phase PHASE1
NCT04544592 UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL Status RECRUITING Phase PHASE1/PHASE2
NCT04534634 Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia(R/R-ALL) Status UNKNOWN Phase PHASE2
NCT04448834 Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL Status WITHDRAWN Phase PHASE2